All analyses
AI analysis

Chemanex Plc: research report

UndervaluedneutralOct 30, 2026

Evidence is balanced: a 0.56 times book value supports Chemanex, but September profit fell 65.0%, leaving a neutral assessment. The latest quarter delivered the weakest net margin in 12 observations.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why balanced

  • The shares trade at 0.56 times book value, placing P/B in the cheapest 4% of manufacturing peers.
  • Audited FY2026 net profit grew 37.6%, showing that the prior full year strengthened despite the latest quarter.
  • Debt was only 3.8% of owners' equity at March 2026, limiting balance-sheet pressure.

Against this. September-quarter net profit fell 65.0% year-on-year and its 3.6% net margin was the weakest of 12 comparable quarters.

Operating margin
13.0%sector 11.3%
from 15.5% a year earlier
Net margin
3.7%sector 6.6%
from 8.9% a year earlier, revenue -15.3%
Return on equity
4.4%
twelve months to Sep 30, 2026, unaudited
P/E
12.8sector 12.8
earnings Rs 11.69 per share, year to Sep 2026
P/B
0.56sector 1.70
book Rs 266.21 per share
Dividend yield
1.67%sector 1.62%
21.4% of earnings paid out

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Oct 30, 2026. Sector figures are the median of 29 listed companies in the same sector.

Overview

Chemanex supplies specialist industrial chemicals, technical formulations and imported raw materials to Sri Lankan manufacturers, alongside a portfolio of strategic investments. Its latest filed quarter was materially weaker than the prior year, while the audited year to March 2026 had improved.

The moderately undervalued market-wide band is the starting point, but the sharp September earnings reversal offsets the low price-to-book valuation. The assessment therefore ends neutral rather than bullish.

Price performance

CHMX closed at LKR 150.00 on 30 October 2026. It fell 18.8% over one year against an 11.6% ASPI decline, and fell 11.5% over six months versus 11.0% for the index, so its longer-term retreat was slightly deeper than the market's.

The close stood only 8.7% through its 52-week range from the low, while 60-day volatility was 15.9% above its own one-year norm. The record since November 2023 is four falls of 15% or more, the deepest 27%, which took eight months to recover.

Liquidity is exceptionally limited: a LKR 1 million order is more than everything that trades on a typical day, at 1730% of it. Building or exiting a position of that size represents far more than a normal session's turnover.

Valuation

At 14.8 times P/E, the market price is LKR 14.80 for every LKR 1 of trailing profit, above the manufacturing median of 12.1 times and at the 68th percentile among peers. At 0.56 times P/B, it is paying 56 cents for each LKR 1 of net assets and sits in the cheapest 4% of the sector on that measure.

The sector comparison and Chemanex's own record point in different directions. The P/E is more expensive than at 9 of the last 13 year-ends, while P/B is more expensive than at 11 of 13 year-ends, despite being unusually low against current peers. The audited FY2026 return on equity was 3.9%, so the low P/B is not matched by a high return on the asset base.

The 1.7% dividend yield is below the sector median and in the lowest 19% of sector yields. DPS was LKR 2.50 in FY2026, after LKR 7.36 in FY2025 and LKR 2.43 in FY2024; the latest year may be incomplete. The LKR 2.50 dividend's ex-date was 1 July 2026, so a buyer today does not receive it.

News and sentiment

Direct coverage is thin, with no material company articles in the last 90 days. The only material item provided reported the FY2026 final dividend on 26 May 2026; its LKR 2.50 per share payment was completed in July.

Financials

The September 2026 quarter weakened year-on-year: revenue fell 15.3%, operating profit fell 28.8%, and net profit fell 65.0%. Gross margin was 27.5% versus 26.5% a year earlier, operating margin was 13.0% versus 15.5%, and net margin was 3.6% versus 8.8%. The gross margin was middling against prior September quarters, but operating margin ranked among the worst and net margin was the worst of 12 comparable quarters.

The LKR 22.7 million gap between operating and net profit, versus LKR 19.0 million a year earlier, shows that finance costs, tax, associates and FX took more from a smaller operating result. The latest balance sheet uses 16.2 million shares, compared with 15.7 million a year earlier, while owners' equity fell to LKR 4.3 billion from LKR 4.5 billion.

The audited year to March 2026 was stronger, with revenue up 25.1% and net profit up 37.6%. That annual result is historical rather than a measure of the September quarter's momentum.

Risks

The largest current risk is earnings variability rather than leverage. September net profit was LKR 8.8 million, down from LKR 25.3 million a year earlier, and the weakest net margin in the available comparable record means the trailing P/E rests on earnings that have recently deteriorated.

The March 2026 balance sheet was conservatively financed, with LKR 159 million of debt, gearing of 3.8% of owners' equity and interest cover of 8.05 times. Interest cover means operating profit covered the interest bill about eight times, reducing immediate lender pressure. However, cash conversion was 0.45 times, meaning less than half of operating profit arrived as operating cash flow in the audited year.

Chemanex imports chemicals and relies on overseas suppliers. As at 30 October 2026, the rupee had weakened and oil had risen sharply amid supply disruptions; these are market conditions, not reported company impacts, but they add cost and currency uncertainty to a distribution-led importer.

Outlook

As at 30 October 2026, the next specific evidence is the interim quarter ending 31 December 2026, expected to be filed between 4 and 14 February 2027. It will show whether the September profit contraction was confined to that quarter or persisted into the following period.

The data cannot establish how currency and energy conditions have affected Chemanex's purchasing costs or customer demand. The next filing is therefore more informative than the limited company news flow.

About this report. Generated on Oct 30, 2026 from market data up to Oct 30, 2026, 0 material news articles over 90 days and financials to Sep 30, 2026, and scored 72 of 100 on value (moderately undervalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports